Mesoangioblast delivery of miniagrin ameliorates murine model of merosin-deficient congenital muscular dystrophy type 1A

Skeletal Muscle

Volumn 5, Issue 1, 2015, Pages

  Domi, Teuta ^a   Porrello, Emanuela ^a   Velardo, Daniele ^a   Capotondo, Alessia ^a   Biffi, Alessandra ^a   Tonlorenzi, Rossana ^a   Amadio, Stefano ^a   Ambrosi, Alessandro ^b   Miyagoe Suzuki, Yuko ^c   Takeda, Shin'ichi ^c   Ruegg, Markus A ^d   Previtali, Stefano Carlo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Congenital muscular dystrophy; Laminin; Mesoangioblast; Miniagrin; Therapy

Indexed keywords

EID: 84940773606     PISSN: None     EISSN: 20445040     Source Type: Journal    
DOI: 10.1186/s13395-015-0055-5     Document Type: Article

References (56)

1. Voit T, Tome F. The congenital muscular dystrophies. In: Engel A, Franzini-Armstrong C, editors. Myology. New York: McGrawHill; 2004. p. 1203-38.
2. Jimenez-Mallebrera C, Brown SC, Sewry CA, Muntoni F. Congenital muscular dystrophy: molecular and cellular aspects. Cell Mol Life Sci. 2005;62(7-8):809-23.
3. Patton B, Miner J, Chiu A, Sanes J. Distribution and function of laminins in the neuromuscular system of developing, adult, and mutant mice. J Cell Biol. 1997;139:1507-21.
4. Previtali SC, Nodari A, Taveggia C, Pardini C, Dina G, Villa A, et al. Expression of laminin receptors in schwann cell differentiation: evidence for distinct roles. J Neurosci. 2003;23(13):5520-30.
5. Durbeej M. Laminins. Cell Tissue Res. 2010;339(1):259-68.
6. Colognato H, Winkelmann D, Yurchenco P. Laminin polymerization induces a receptor-cytoskeleton network. J Cell Biol. 1999;145:619-31.
7. Mayer U, Saher G, Fassler R, Bornemann A, Echtermeyer F, von der Mark H, et al. Absence of integrin alpha 7 causes a novel form of muscular dystrophy. Nat Genet. 1997;17(3):318-23.
8. Feltri M, Graus-Porta D, Previtali S, Nodari A, Migliavacca B, Cassetti A, et al. Conditional disruption of beta1 integrin in Schwann cells impedes interactions with axons. J Cell Biol. 2002;156:199-209.
9. Saito F, Moore SA, Barresi R, Henry MD, Messing A, Ross-Barta SE, et al. Unique role of dystroglycan in peripheral nerve myelination, nodal structure, and sodium channel stabilization. Neuron. 2003;38(5):747-58.
10. Pellegatta M, De Arcangelis A, D'Urso A, Nodari A, Zambroni D, Ghidinelli M, et al. alpha6beta1 and alpha7beta1 integrins are required in Schwann cells to sort axons. J Neurosci. 2013;33(46):17995-8007.
11. Previtali SC, Dina G, Nodari A, Fasolini M, Wrabetz L, Mayer U, et al. Schwann cells synthesize alpha7beta1 integrin which is dispensable for peripheral nerve development and myelination. Mol Cell Neurosci. 2003;23(2):210-8.
12. Schwander M, Leu M, Stumm M, Dorchies OM, Ruegg UT, Schittny J, et al. Beta1 integrins regulate myoblast fusion and sarcomere assembly. Dev Cell. 2003;4(5):673-85.
13. Cohn RD, Henry MD, Michele DE, Barresi R, Saito F, Moore SA, et al. Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. Cell. 2002;110(5):639-48.
14. Meier H, Southard JL. Muscular dystrophy in the mouse caused by an allele at the dy-locus. Life Sci. 1970;9(3):137-44.
15. Xu H, Wu X-R, Wewer U, Engvall E. Murine muscular dystrophy caused by a mutation in the laminin alpha2 (Lama2) gene. Nature Genet. 1994;1994:297-302.
16. Sunada Y, Bernier S, Utani A, Yamada Y, Campbell K. Identification of a novel mutant transcript of laminin alpha2 chain gene responsible for muscular dystrophy and dysmyelination in dy2J mice. Hum Mol Genet. 1995;4:1055-61.
17. Miyagoe Y, Hanaoka K, Nonaka I, Hayasaka M, Nabeshima Y, Arahata K, et al. Laminin alpha2 chain-null mutant mice by targeted disruption of the lama2 gene: a new model of merosin (laminin 2)-deficient congenital muscular dystrophy. FEBS. 1997;415:33-9.
18. Guo LT, Zhang XU, Kuang W, Xu H, Liu LA, Vilquin JT, et al. Laminin alpha2 deficiency and muscular dystrophy; genotype-phenotype correlation in mutant mice. Neuromuscul Disord. 2003;13(3):207-15.
19. Moll J, Barzaghi P, Lin S, Bezakova G, Lochmuller H, Engvall E, et al. An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature. 2001;413(6853):302-7.
20. Meinen S, Barzaghi P, Lin S, Lochmuller H, Ruegg MA. Linker molecules between laminins and dystroglycan ameliorate laminin-alpha2-deficient muscular dystrophy at all disease stages. J Cell Biol. 2007;176(7):979-93.
21. Bentzinger CF, Barzaghi P, Lin S, Ruegg MA. Overexpression of mini-agrin in skeletal muscle increases muscle integrity and regenerative capacity in laminin-alpha2-deficient mice. FASEB J. 2005;19(8):934-42.
22. Talts JF, Sasaki T, Miosge N, Gohring W, Mann K, Mayne R, et al. Structural and functional analysis of the recombinant G domain of the laminin alpha4 chain and its proteolytic processing in tissues. J Biol Chem. 2000;275(45):35192-9.
23. Ringelmann B, Roder C, Hallmann R, Maley M, Davies M, Grounds M, et al. Expression of laminin alpha1, alpha2, alpha4, and alpha5 chains, fibronectin, and tenascin-C in skeletal muscle of dystrophic 129ReJ dy/dy mice. Exp Cell Res. 1999;246(1):165-82.
24. Qiao C, Li J, Zhu T, Draviam R, Watkins S, Ye X, et al. Amelioration of laminin-alpha2-deficient congenital muscular dystrophy by somatic gene transfer of miniagrin. Proc Natl Acad Sci U S A. 2005;102(34):11999-2004.
25. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012-an update. J Gene Med. 2013;15(2):65-77.
26. O'Reilly M, Federoff HJ, Fong Y, Kohn DB, Patterson AP, Ahmed N, et al. Gene therapy: charting a future course-summary of a National Institutes of Health Workshop, April 12, 2013. Hum Gene Ther. 2014;25(6):488-97.
27. Meng J, Muntoni F, Morgan JE. Stem cells to treat muscular dystrophies-where are we? Neuromuscul Disord. 2011;21(1):4-12.
28. Partridge TA. Impending therapies for Duchenne muscular dystrophy. Curr Opin Neurol. 2011;24(5):415-22.
29. Biffi A, De Palma M, Quattrini A, Del Carro U, Amadio S, Visigalli I, et al. Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J Clin Invest. 2004;113(8):1118-29.
30. Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341(6148):1233158.
31. Minasi MG, Riminucci M, De Angelis L, Borello U, Berarducci B, Innocenzi A, et al. The meso-angioblast: a multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. Development. 2002;129(11):2773-83.
32. Sampaolesi M, Blot S, D'Antona G, Granger N, Tonlorenzi R, Innocenzi A, et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature. 2006;444(7119):574-9.
33. Sampaolesi M, Torrente Y, Innocenzi A, Tonlorenzi R, D'Antona G, Pellegrino MA, et al. Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science. 2003;301(5632):487-92.
34. Diaz-Manera J, Touvier T, Dellavalle A, Tonlorenzi R, Tedesco FS, Messina G, et al. Partial dysferlin reconstitution by adult murine mesoangioblasts is sufficient for full functional recovery in a murine model of dysferlinopathy. Cell Death Dis. 2010;1, e61.
35. Berry SE, Liu J, Chaney EJ, Kaufman SJ. Multipotential mesoangioblast stem cell therapy in the mdx/utrn-/- mouse model for Duchenne muscular dystrophy. Regen Med. 2007;2(3):275-88.
36. Tedesco FS, Gerli MF, Perani L, Benedetti S, Ungaro F, Cassano M, et al. Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy. Sci Transl Med. 2012;4(140):140ra189.
37. Tonlorenzi R, Dellavalle A, Schnapp E, Cossu G, Sampaolesi M. Isolation and characterization of mesoangioblasts from mouse, dog, and human tissues. Curr Protoc Stem Cell Biol. 2007;Chapter 2:Unit 2B 1.
38. Triolo D, Dina G, Lorenzetti I, Malaguti M, Morana P, Del Carro U, et al. Loss of glial fibrillary acidic protein (GFAP) impairs Schwann cell proliferation and delays nerve regeneration after damage. J Cell Sci. 2006;119(Pt 19):3981-93.
39. Porrello E, Rivellini C, Dina G, Triolo D, Del Carro U, Ungaro D, et al. Jab1 regulates Schwann cell proliferation and axonal sorting through p27. J Exp Med. 2014;211(1):29-43.
40. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57:289-300.
41. Fuoco C, Salvatori ML, Biondo A, Shapira-Schweitzer K, Santoleri S, Antonini S, et al. Injectable polyethylene glycol-fibrinogen hydrogel adjuvant improves survival and differentiation of transplanted mesoangioblasts in acute and chronic skeletal-muscle degeneration. Skelet Muscle. 2012;2(1):24.
42. Montesano A, Luzi L, Senesi P, Terruzzi I. Modulation of cell cycle progression by 5-azacytidine is associated with early myogenesis induction in murine myoblasts. Int J Biol Sci. 2013;9(4):391-402.
43. Hupkes M, Jonsson MK, Scheenen WJ, van Rotterdam W, Sotoca AM, van Someren EP, et al. Epigenetics: DNA demethylation promotes skeletal myotube maturation. Faseb J. 2011;25(11):3861-72.
44. Hagiwara H, Saito F, Masaki T, Ikeda M, Nakamura-Ohkuma A, Shimizu T, et al. Histone deacetylase inhibitor trichostatin A enhances myogenesis by coordinating muscle regulatory factors and myogenic repressors. Biochem Biophys Res Commun. 2011;414(4):826-31.
45. Carmignac V, Quere R, Durbeej M. Proteasome inhibition improves the muscle of laminin alpha2 chain-deficient mice. Hum Mol Genet. 2011;20(3):541-52.
46. Girgenrath M, Dominov JA, Kostek CA, Miller JB. Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy. J Clin Invest. 2004;114(11):1635-9.
47. Yu Q, Sali A, Van der Meulen J, Creeden BK, Gordish-Dressman H, Rutkowski A, et al. Omigapil treatment decreases fibrosis and improves respiratory rate in dy(2J) mouse model of congenital muscular dystrophy. PLoS ONE. 2013;8(6), e65468.
48. Mayer U. Integrins: redundant or important players in skeletal muscle? J Biol Chem. 2003;278(17):14587-90.
49. Di Muzio A, De Angelis MV, Di Fulvio P, Ratti A, Pizzuti A, Stuppia L, et al. Dysmyelinating sensory-motor neuropathy in merosin-deficient congenital muscular dystrophy. Muscle Nerve. 2003;27(4):500-6.
50. Shorer Z, Philpot J, Muntoni F, Sewry C, Dubowitz V. Demyelinating peripheral neuropathy in merosin-deficient congenital muscular dystrophy. J Child Neurol. 1995;10:472-5.
51. Weiss A, Leinwand LA. The mammalian myosin heavy chain gene family. Annu Rev Cell Dev Biol. 1996;12:417-39.
52. Lapidos KA, Chen YE, Earley JU, Heydemann A, Huber JM, Chien M, et al. Transplanted hematopoietic stem cells demonstrate impaired sarcoglycan expression after engraftment into cardiac and skeletal muscle. J Clin Invest. 2004;114(11):1577-85.
53. Meinen S, Ruegg MA. Congenital muscular dystrophy: mini-agrin delivers in mice. Gene Ther. 2006;13(11):869-70.
54. Meyer U. Integrins: redundant or important players in skeletal muscle. J Biol Chem. 2003;278:14587-90.
55. Tedesco FS, Hoshiya H, D'Antona G, Gerli MF, Messina G, Antonini S, et al. Stem cell-mediated transfer of a human artificial chromosome ameliorates muscular dystrophy. Sci Transl Med. 2011;3(96):96ra78.
56. Kuang W, Xu H, Vachon P, Liu L, Loechel F, Wewer U, et al. Merosin-deficient congenital muscular dystrophy. J Clin Invest. 1998;102:844-52.